When direct oral anticoagulants (DOACs) were developed, they were meant to entirely substitute vitamin K antagonists (VKAs) in the prevention of thromboembolism and stroke in patients with atrial ...

To assess the relationship between the etiology, clinical pattern, and recurrence, a retrospective analysis of the dabigatran treatment of acute stroke II (DATAS II) trial was done. This included 305 ...

Dabigatran also had similar rates of major bleeding and intracranial hemorrhage compared with aspirin (risk differences, 0.5 [95 percent confidence interval, −2.1 to 19.6] and 0.0 [95 percent ...

Apixaban and dabigatran had similar rates of major bleeding compared with low-dose aspirin. In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single ...

The anticoagulants apixaban and dabigatran do not cause more bleeding than aspirin when treating stroke or atrial fibrillation, according to an analysis of randomized clinical trials published in ...